Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Malaria Therapeutics Market is projected to expand from a valuation of USD 3.05 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a compound annual growth rate of 14.07%. This sector encompasses a specialized category of pharmaceutical agents, such as artemisinin-based combination therapies and prophylactic drugs, developed to treat and prevent infections caused by Plasmodium parasites. Market momentum is primarily sustained by the persistent global disease burden, which necessitates effective treatment protocols and chemoprevention strategies, further bolstered by strong backing from international health organizations and donor agencies focused on prioritizing access to essential medicines in endemic areas. Highlighting the urgent public health needs driving this industry, the World Health Organization estimated there were 282 million global malaria cases in 2024.

Conversely, market growth faces a substantial obstacle in the form of increasing antimalarial drug resistance, specifically partial resistance to artemisinin derivatives observed in high-burden territories. This biological adaptation undermines the effectiveness of standard-of-care regimens, requiring the creation of more intricate and expensive alternative treatments. As a result, the viability of existing affordable therapies is jeopardized, establishing logistical and financial barriers that limit the widespread commercial adoption of next-generation therapeutic solutions.

Market Drivers

A primary factor accelerating the Global Malaria Therapeutics Market is the significant increase in funding from international health bodies, which effectively subsidizes the procurement and distribution of essential antimalarials and preventative treatments. This capital infusion is vital for bridging the gap between high drug development costs and the low purchasing power of endemic regions, ensuring that novel therapies reach patient populations. For example, The Global Fund approved US$9.2 billion in new grants in January 2024 to speed up the battle against HIV, tuberculosis, and malaria for the 2024-2026 period. Such investments directly facilitate the scaling of intervention strategies, including the deployment of next-generation medical tools. Consequently, the market is witnessing a rapid uptake of new preventive measures; Gavi, the Vaccine Alliance, reported in December 2024 that over 12 million malaria vaccine doses had been procured and shipped to endemic countries since the rollout began.

Concurrently, the market is expanding due to the rising incidence of malaria in high-burden regions, a trend exacerbated by climate change and widening mosquito habitats. Environmental shifts are prolonging transmission seasons and expanding the geographical range of vectors, thereby raising the volume of patients requiring immediate therapeutic intervention. This persistent demand generates a sustained commercial requirement for both artemisinin-based combination therapies and emerging alternative drugs. The urgency of this demand is highlighted by recent epidemiological data; the World Health Organization noted in December 2024 that global malaria cases rose by approximately 11 million in 2023 compared to the prior year, reinforcing the critical need for continuous supply and innovation in therapeutic regimens to manage the growing patient load effectively.

Market Challenges

Antimalarial drug resistance constitutes a major hurdle significantly restricting the growth of the global malaria therapeutics market. This biological evolution renders standard-of-care treatments, specifically artemisinin-based combination therapies, increasingly ineffective, compelling pharmaceutical developers to redirect significant capital toward the high-risk discovery of novel compounds. The necessity to replace established, low-cost generics with complex next-generation molecules creates severe financial strain and extends research timelines. Consequently, the market encounters a productivity bottleneck where the scalability of affordable solutions is compromised, generating uncertainty for investors and delaying the commercial rollout of essential new medicines that are vital for revenue generation.

Furthermore, the proliferation of resistance necessitates rigorous and expensive surveillance mechanisms to monitor therapeutic efficacy, thereby draining healthcare budgets in endemic nations. This economic pressure reduces the available funds for purchasing advanced therapeutics, limiting the market penetration of newer, higher-priced drugs. The magnitude of this issue is evident in recent data regarding the spread of resistant strains; according to the World Health Organization, in 2024, partial resistance to artemisinin derivatives was confirmed or suspected in at least eight countries within the African region. This trend not only threatens clinical outcomes but also creates a volatile commercial environment where manufacturers must constantly adapt to the diminishing lifespan of their existing product portfolios.

Market Trends

The introduction of novel non-artemisinin drug classes constitutes a critical trend aimed at circumventing the widespread issue of partial resistance to standard artemisinin-based therapies. Pharmaceutical developers are prioritizing compounds with alternative mechanisms of action to ensure continued therapeutic efficacy against evolving parasite strains. This shift is exemplified by the advancement of next-generation combinations such as ganaplacide-lumefantrine, which are designed to clear infections independent of artemisinin susceptibility and block transmission. According to Novartis, in November 2025, the Phase 3 clinical trial for this novel non-artemisinin candidate achieved a PCR-corrected efficacy of 97.4% in treating uncomplicated malaria, meeting the primary endpoint of non-inferiority to current standards.

Simultaneously, the market is experiencing a significant expansion of pediatric-specific dispersible formulations intended to improve treatment adherence and outcomes among the most vulnerable patient demographic. Manufacturers are increasingly moving away from adult tablets that require crushing, instead scaling the production of soluble, palatable options that ensure accurate dosing for children. This focus on child-friendly delivery systems has led to massive procurement volumes supported by global health partnerships to bridge the access gap in endemic countries. According to Medicines for Malaria Venture, in April 2025, the cumulative global distribution of the pediatric treatment Coartem Dispersible reached a landmark 500 million courses, underscoring the industrial scale-up dedicated to reducing mortality in children under five.

Key Players Profiled in the Malaria Therapeutics Market

• Novartis AG
• Sanofi S.A
• Pfizer Inc.
• GlaxoSmithKline PLC
• Merck & Co Inc.
• F. Hoffmann-La Roche AG
• Cipla Limited
• Ajanta Pharma Limited

Report Scope

In this report, the Global Malaria Therapeutics Market has been segmented into the following categories:

Malaria Therapeutics Market, by Drug Type:

• Artemisinin-based combination therapy (ACT)
• Quinine
• Chloroquine
• Others

Malaria Therapeutics Market, by Drug Formulation:

• Tablets
• Capsules
• Injectables
• Others

Malaria Therapeutics Market, by End User:

• Adults
• Children
• Pregnant Women
• Others

Malaria Therapeutics Market, by Distribution Channel:

• Retail pharmacies
• Hospitals
• Online pharmacies

Malaria Therapeutics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Therapeutics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.